Health Innovation Manchester, part of the Health Innovation Network, has announced a groundbreaking strategic partnership with Eli Lilly and Company (Lilly) to initiate a five-year real-world evidence study (SURMOUNT-REAL UK), subject to relevant approvals.
The study will evaluate the real-world effectiveness of tirzepatide in weight loss, diabetes prevention, and prevention of obesity-related complications for adults with obesity. Tirzepatide is an injected medication which lowers blood sugar levels (1). The evidence generated will seek to increase the global evidence base on the long-term impacts of weight loss medicines and potentially inform the UK’s care pathway approach to the treatment of obesity.
Significantly, the five-year study will also aim to collect data on healthcare resource utilisation, health-related quality of life and changes in participants’ employment status and absence from work.
Health Innovation Manchester has worked with the University of Manchester and local digital trials company NorthWest EHealth (NWEH) to develop the study approach.
“Greater Manchester (GM) is well placed to deliver novel trials and real-world evidence studies to develop a deeper understanding of the impact that industry-led innovation can have on population health. Through this landmark partnership with Lilly we will show how a medicine impacts people’s long-term health outcomes. This will help us understand its effects people with obesity in GM as well as inform national strategies and pave the way for further research and development in this critical area.”
“At Lilly, we are deeply committed to improving lives by partnering across the health system to address complex health challenges like obesity. We’re delighted to partner with Health Innovation Manchester on our plans for the SURMOUNT-REAL UK study. This collaboration will add to the evidence base on the real world impact of obesity treatments on the health of people with obesity, and will explore a broad range of outcomes including health-related quality of life and impact on individuals’ employment status.”
“Around 600,000 adults in Greater Manchester live with obesity, many of whom also suffer with other obesity-related illnesses which reduces their quality of life and puts additional pressure on the health and care system. Working collaboratively with industry to solve these problems is paramount, and I am delighted to support the study coming to the Greater Manchester integrated care system.”
Do you have a great idea that could deliver meaningful change in the real world?
Get involved